已收盤 11-06 16:00:00 美东时间
+0.012
+1.45%
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics Update follows SRX’s previously announced definitive agreement to acquire CERo Therapeutics NORTH PALM BEACH, Fla., Oct. 26, 2026 (GLOBE NEWS...
10-26 21:09
SRX Global announced the activation of UC Davis as a clinical trial site for the Phase 1 CERTAIN-T study evaluating CER-1236 in hematologic malignancies. UC Davis also serves as the primary manufacturing site for CER-1236, expected to enhance patient recruitment and streamline treatment logistics. This milestone follows SRX's definitive agreement to acquire CERo Therapeutics. The activation strengthens CERo's clinical trial capabilities and suppo...
10-26 13:05
SRX Global Inc. (NYSE American: SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced a $1.5 million commitment to launch a new family of actively man...
10-07 04:23
SRX Global Inc. announced that its CEO, Kent Cunningham, and President, Eric Jackson, will present at the Webull Corporate Connect Series Fintech Investment Webinar on September 30, 2026, at 1:00 p.m. ET. Interested parties can register via the provided link or the Webull mobile app, requiring a free account. A replay will be available post-event.
09-23 20:05
SRx Health Solutions ( ($SRXH) ) has provided an update. On August 27, 2026, SR...
09-10 03:27
SRX Global has invested in CERo Therapeutics to support development of its lead therapy, CER-1236, for hematological cancers. The investment aims to accelerate clinical programs and R&D efforts. CERo's Phase 1 CERTAIN-T trial has treated six patients, with no dose-limiting toxicities observed at higher doses. The trial is expanding to include myelodysplastic syndromes and myelofibrosis. SRX CEO Kent Cunningham highlighted CERo's innovative approa...
08-31 11:30
SRx Health Solutions ( ($SRXH) ) has provided an update. On August 27, 2026, SR...
08-29 05:32
SRX Global Inc. has acquired a stake in Vistagen Therapeutics, Inc., a biopharmaceutical company developing intranasal neuroscience products. SRX views Vistagen's shares as undervalued and aims to engage with its leadership to unlock shareholder value. SRX is an AI-driven platform focused on long-term investments in high-conviction companies and strategic assets.
08-04 09:00
Jersey Mike’s Subs Inc. (NYSE:JMKE) stepped onto the public stage Friday, beginning its first day of trading on the New York Stock Exchange after setting its offering price at $23 per share and securing a total valuation of $1 billion at that level. Here’s what you need to know. Jersey Mike’s Subs s...
07-31 23:00
SRX Global Inc. (NYSE:SRXH) (the "Company", or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it acquired shares in the initial public offering of Jersey Mike’s, ...
07-31 02:08